Relations between arthralgia and fear of recurrence: results of a cross-sectional study of breast cancer patients treated with adjuvant aromatase inhibitors therapy

Supportive Care in Cancer

Volumn 23, Issue 12, 2015, Pages 3581-3588

  Lopez, Clémentine ^a   Charles, Cécile ^a,b   Rouby, Pascal ^a   Boinon, Diane ^a   Laurent, Sophie ^a   Rey, Annie ^a   Spielmann, Marc ^a   Dauchy, Sarah ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Paris Descartes University Sorbonne Paris Cité   (France)

Author keywords

Aromatase inhibitors; Arthralgia; Fear of recurrence; Quality of life

Indexed keywords

AROMATASE INHIBITOR;

ACUPUNCTURE; ADJUVANT THERAPY; ADULT; AGED; ANALGESIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEAR; FEMALE; HUMAN; HYPNOSIS; MAJOR CLINICAL STUDY; MALE; PAIN INTENSITY; PAIN SEVERITY; PHYSIOTHERAPY; PRIORITY JOURNAL; RELAXATION TRAINING; SHORT FORM 36; ANXIETY; BREAST NEOPLASMS; DEPRESSION; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRE; TUMOR RECURRENCE;

AGED; ANXIETY; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; DEPRESSION; FEAR; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 84945441183     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2722-9     Document Type: Article

References (45)

1. Aydiner A (2013) Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women. Breast 22:121–129
2. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:1299–1309
3. Niravath P (2013) Aromatase inhibitor-induced arthralgia: a review. Ann Oncol 24:1443–1449
4. Gaillard S, Stearns V (2011) Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 13:205
5. Buzdar A, Howell A, Cuzick J et al (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633–643
6. Coates AS, Keshaviah A, Thürlimann B et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol 25:486–492
7. Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559–570
8. Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271
9. Takei H, Ohsumi S, Shimozuma K, Takehara M, Suemasu K, Ohashi Y, Hozumi Y (2012) Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04). Breast Cancer Res Treat 133:227–236
10. Fallowfield LJ, Kilburn LS, Langridge C, Snowdon CF, Bliss JM, Coombes RC (2012) Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br J Cancer 106:1062–1067
11. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A (2006) Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100:273–284
12. van Nes JG, Fontein DB, Hille ET, Voskuil DW, van Leeuwen FE, de Haes JC, Putter H, Seynaeve C, Nortier JW, van de Velde CJ (2012) Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast Cancer Res Treat 134:267–276
13. Whelan TJ, Goss PE, Ingle JN et al (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23:6931–6940
14. Laroche F, Coste J, Medkour T et al (2014) Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study. J Pain 15:293–303
15. Olufade T, Gallicchio L, MacDonald R, Helzlsouer KJ (2015) Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors. Support Care Cancer 23:447–455
16. Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115:3631–3639
17. Henry NL, Giles JT, Ang D et al (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111:365–372
18. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877–3883
19. Presant CA, Bosserman L, Young T, Vakil M, Horns R, Upadhyaya G, Ebrahimi B, Yeon C, Howard F (2007) Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 7:775–778
20. Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, Gralow J (2008) Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry 30:112–126
21. Reich M, Lesur A, Perdrizet-Chevallier C (2008) Depression, quality of life and breast cancer: a review of the literature. Breast Cancer Res Treat 110:9–17
22. Crist JV, Grunfeld EA (2013) Factors reported to influence fear of recurrence in cancer patients: a systematic review. Psychooncology 22:978–986
23. van den Beuken-van Everdingen MH, Peters ML, de Rijke JM, Schouten HC, van Kleef M, Patijn J (2008) Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study. Psychooncology 17:1137–1145
24. Janz NK, Hawley ST, Mujahid MS, Griggs JJ, Alderman A, Hamilton AS, Graff JJ, Jagsi R, Katz SJ (2011) Correlates of worry about recurrence in a multiethnic population-based sample of women with breast cancer. Cancer 117:1827–1836
25. Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, Ozakinci G (2013) Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv 7:300–322
26. Leventhal H, Diefenbach M, Leventhal EA (1992) Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cognit Ther Res 16:143–163
27. Lee-Jones C, Humphris G, Dixon R, Hatcher MB (1997) Fear of cancer recurrence–a literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Psychooncology 6:95–105
28. Corter AL, Findlay M, Broom R, Porter D, Petrie KJ (2013) Beliefs about medicine and illness are associated with fear of cancer recurrence in women taking adjuvant endocrine therapy for breast cancer. Br J Health Psychol 18:168–181
29. Leplège A, Ecosse E, Verdier A, Perneger TV (1998) The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 51:1013–1023
30. Furlanetto LM, Mendlowicz MV, Romildo Bueno J (2005) The validity of the Beck Depression Inventory-Short Form as a screening and diagnostic instrument for moderate and severe depression in medical inpatients. J Affect Disord 86:87–91
31. Bruchon-Schweitzer M, Paulhan I (1993) Manuel de l'inventaire d'anxiété état-trait forme Y (STAI-Y) de Spielberger. Editions du Centre de Psychologie Appliquée, Paris
32. Simard S, Savard J (2009) Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer 17:241–251
33. Paul SM, Zelman DC, Smith M, Miaskowski C (2005) Categorizing the severity of cancer pain: further exploration of the establishment of cutpoints. Pain 113:37–44
34. Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, Van Dam FS, Schagen SB (2009) Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 48:76–85
35. Cunningham NR, Kashikar-Zuck S (2013) Nonpharmacological treatment of pain in rheumatic diseases and other musculoskeletal pain conditions. Curr Rheumatol Rep 15:306
36. Mao JJ, Xie SX, Farrar JT, Stricker CT, Bowman MA, Bruner D, DeMichele A (2014) A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use. Eur J Cancer 50:267–276
37. Bao T, Cai L, Giles JT et al (2013) A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors. Breast Cancer Res Treat 138:167–174
38. Simard S, Savard J, Ivers H (2010) Fear of cancer recurrence: specific profiles and nature of intrusive thoughts. J Cancer Surviv 4:361–371
39. Alford BA, Beck AT (1997) The integrative power of cognitive therapy. The Guilford Press, New York
40. Osborn RL, Demoncada AC, Feuerstein M (2006) Psychosocial interventions for depression, anxiety, and quality of life in cancer survivors: meta-analyses. Int J Psychiatry Med 36:13–34
41. Herschbach P, Book K, Dinkel A, Berg P, Waadt S, Duran G, Engst-Hastreiter U, Henrich G (2010) Evaluation of two group therapies to reduce fear of progression in cancer patients. Support Care Cancer 18:471–479
42. Ehde DM, Dillworth TM, Turner JA (2014) Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and directions for research. Am Psychol 69:153–166
43. Sturgeon JA (2014) Psychological therapies for the management of chronic pain. Psychol Res Behav Manag 7:115–124
44. Watson CP, Gilron I, Sawynok J, Lynch ME (2011) Nontricyclic antidepressant analgesics and pain: are serotonin norepinephrine reuptake inhibitors (SNRIs) any better? Pain 152:2206–2210
45. Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, Griggs JJ, Hayes DF (2011) Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer 117:5469–5475